Since viral proteins suppress the STING pathway in the early stage of infection, while the micronucleus and DNA damage caused by cell fusion in the host activate the STING signaling to suppress viral infection, treatment with STING agonists in the early stage of COVID-19 provides be a potential antiviral strategy. This evidence concerns the gene STING1 and viral infectious disease.